Vincristine

Generic Name: Vincristine

Brand Names: Marqibo, Vincasar

Drug Type: Small Molecule

Chemical Formula: C_₄₆H_₅₆N_₄O_₁₀

CAS Number: 57-22-7

Unique Ingredient Identifier: 5J49Q6B70F

Background: Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristin...

Indication: Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions: Acute Lymphoblastic Leukemia (ALL), Choriocarcinoma, Chronic Lymphocytic Leukemia, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Hepatoblastomas, Hodgkin's Lymphoma, Immune Thrombocytopenia (ITP), Kaposi's Sarcoma, Multiple Myeloma (MM), Neuroblastoma (NB), Non-Hodgkin's Lymphoma (NHL), Ovarian germ cell tumour, Pheochromocytoma, Relapsed Acute Lymphoblastic Leukemia (ALL), Retinoblastoma, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Wilms' tumor, Advanced Thymoma

Associated Therapies: -

Clinical Trials

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Phase 1

Recruiting

Conditions: Rhabdomyosarcoma

Interventions: Radiation: radiotherapy
Drug: Irinotecan
Drug: Vinorelbine
Drug: Actinomycin D
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Ifosfamide
Drug: Temozolomide
Drug: Regorafenib
Drug: Vincristine

First Posted Date: 2020-11-12

Last Posted Date: 2024-05-23

Lead Sponsor: University of Birmingham

Target Recruit Count: 1672

Registration Number: NCT04625907

Locations: 🇬🇷
University Unit of Pediatric Oncology-hematology - Children's Hospital Agia Sophia, Athens, Greece
🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱
Hadassah University Medical Centre, Jerusalem, Israel

and more 125 locations

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: placebo
Drug: acalabrutinib
Drug: Prednisone
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Vincristine
Drug: Doxorubicin

First Posted Date: 2020-08-28

Last Posted Date: 2024-12-19

Lead Sponsor: Acerta Pharma BV

Target Recruit Count: 611

Registration Number: NCT04529772

Locations: 🇺🇦
Research Site, Zaporizhzhia, Ukraine

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Diffuse Large B-Cell Lymphoma

Interventions: Drug: ME-401
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2020-08-18

Last Posted Date: 2023-12-20

Lead Sponsor: Deepa Jagadeesh

Target Recruit Count: 13

Registration Number: NCT04517435

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Phase 2

Not yet recruiting

Conditions: Acute Leukemia of Ambiguous Lineage

Interventions: Drug: vincristine
Drug: daunorubicin
Drug: cyclophosphamide
Drug: L-Asparaginase
Drug: prednisone
Drug: mercaptopurine
Drug: methotrexate
Drug: dexamethasone
Drug: Tyrosine kinase inhibitor

First Posted Date: 2020-06-19

Last Posted Date: 2020-06-19

Lead Sponsor: wang, jianxiang

Target Recruit Count: 50

Registration Number: NCT04440267

Locations: 🇨🇳
HBDH, Tianjin, Tianjin, China

Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement

Phase 1

Recruiting

Conditions: Untreated
DLBCL
MYC Gene Rearrangement

Interventions: Drug: Lenalidomide
Drug: Rituximab
Drug: Etoposide
Drug: Doxorubicin
Drug: Vincristine
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2020-06-16

Last Posted Date: 2020-06-16

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 81

Registration Number: NCT04432714

Locations: 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

Lenalidomide in Combination With CHOP in Patients With Untreated PTCL

Phase 1

Recruiting

Conditions: PTCL, NOS
AITL
ALK- ALCL
Phase III-IV ALK+ ALCL
EATL

Interventions: Drug: Lenalidomide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone

First Posted Date: 2020-06-09

Last Posted Date: 2020-06-16

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 91

Registration Number: NCT04423926

Locations: 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China

Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma

Phase 2

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Drug: Sonidegib
Drug: Lomustine
Drug: Vincristine
Radiation: radiotherapy

First Posted Date: 2020-05-26

Last Posted Date: 2024-08-26

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 20

Registration Number: NCT04402073

Locations: 🇦🇺
Royal Adelaide Hospital, Adelaide, Australia
🇦🇺
Princess Alexandra Hospital - University Of Queensland, Brisbane, Australia
🇦🇺
Austin Health - Austin hospital, Melbourne, Australia

and more 47 locations

Evolutionary Therapy for Rhabdomyosarcoma

Phase 2

Recruiting

Conditions: Rhabdomyosarcoma

Interventions: Drug: Vincristine
Drug: Cyclophosphamide
Drug: Vinorelbine
Drug: Actinomycin D
Drug: Cyclophosphamide Pill

First Posted Date: 2020-05-14

Last Posted Date: 2024-11-28

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 28

Registration Number: NCT04388839

Locations: 🇺🇸
Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States

and more 15 locations

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

First Posted Date: 2020-03-26

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 221

Registration Number: NCT04322318

Locations: 🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
UMass Memorial Medical Center - University Campus, Worcester, Massachusetts, United States

and more 193 locations

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Phase 3

Recruiting

Conditions: High-Risk Neuroblastoma
Patient With Insufficient Response Chemoimmunotherapy

Interventions: Radiation: Radiotherapy
Drug: Vincristine
Drug: Busulfan
Drug: Dinutuximab Beta
Drug: Carboplatin
Drug: Melphalan
Drug: Etoposide
Drug: Thiotepa
Drug: Vindesine
Drug: Dacarbazine
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Cisplatin
Drug: Temozolomide 100 MG
Drug: Irinotecan
Drug: Cyclophosphamid

First Posted Date: 2020-01-09

Last Posted Date: 2024-05-16

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 800

Registration Number: NCT04221035

Locations: 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷
Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹
instituto Giannina Gaslini genova, Genova, Italy

and more 134 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy